



## NHS NORTH WEST LONDON ICS - MESSAGE TO ALL NWL GP PRACTICES

### 15th September 2025

This cancer GP bulletin contains updates for GPs and their practice staff on the following:

#### **MAXIMISING EARLY CANCER DIAGNOSIS**

- 1. Bladder Campaign now LIVE ALL PRACTICE STAFF
- 2. Faecal Immunochemical Testing (FIT) in the Lower Gastrointestinal (GI) pathway Q1 25/26 position (including July 2025) **ALL PRACTICE STAFF**

### **CANCER SCREENING**

1. WSIC Dashboard: how to utilise the dashboard to identify unscreened populations to enable targeted interventions and focused outreach - ALL PRACTICE STAFF

### **BLADDER CAMPAIGN – NOW LIVE DURING SEPTEMBER**

RM Partners Cancer Alliance, in partnership with <u>Action Bladder Cancer UK</u>, is supporting a campaign to help more people recognise the signs and symptoms of bladder cancer and to contact their GP practice early.

The campaign is focusing on people over the age of 50, particularly women (where bladder cancer can often be overlooked due to overlap with symptoms of UTI and menopausal / post-menopausal symptoms) and those from lower socio-economic groups as they are most likely to experience a late-stage cancer diagnosis. It will also include people in this age group from Black and South Asian ethnic backgrounds, who are already at increased risk of health inequalities.

The campaign will run in areas of highest deprivation across 14 boroughs in NWL and SWL on bus shelters, social media and online from **1st of September to 30th of September 2025.** 

Digital and paper posters and materials can be requested via the following website, which also includes information in different languages:

### Bladder Cancer. Same Symptoms. Different Story

Please see attached Primary Care Toolkit with further information and do display posters on your websites and in your surgeries.

Education available to support clinicians





Action Bladder UK have **FREE training modules** available to support primary care.

The latest addition to the programme is a free **online learning module** designed to enhance GP's understanding of the epidemiology of bladder cancer, identify risk factors, recognise how the disease presents, and learn how bladder cancer is investigated and managed in secondary care. Find out more here

## Bladder Campaign Primary Care Toolkit



# FAECAL IMMUNOCHEMICAL TESTING (FIT) IN THE LOWER GASTROINTESTINAL (GI) PATHWAY – Q1 25/26 POSITION (INCLUDING JULY 2025)


### FOR INFORMATION - ALL PRACTICE STAFF

As you will know comprehensive use of FIT in NG12 patients is critical to improving bowel cancer survival in England, ensuring patients on the lower GI pathway can be diagnosed promptly and using available colonoscopy capacity in the most effective way.

For 2025/26, FIT testing is still included in the Investment and Impact Fund (IIF) for PCN delivery as well as the PCN Network DES for Early Cancer Diagnosis:

**CAN 04:** The proportion of patients who have had a lower GI Urgent who have had a lower gastrointestinal urgent suspected cancer referral in the reporting year, where at least one urgent suspected cancer referral was accompanied by a faecal immunochemical test result, with the result recorded in the twenty-one days leading up to the referral.(Upper threshold Target 80% for maximum 22 points)

As at the end of July 2025, FIT compliance for NWL is **78.6%** with individual PCN positions as below:







- The attached document provides practices and PCNs with:
  - Guidance for practices on the efficacy of using FIT to support lower GI referral for Urgent Suspected Cancer (USC)
  - Best practice for maximising patient completion of FIT kits (Accuryx)
  - FIT educational resources for primary care and resources available to support patients (including videos and leaflets in different languages.)

For any further queries/support, please contact your placed based clinical lead:

Central London, West London and Hammersmith and Fulham: Dr Helen Burn (Helen.Burn4@nhs.net)

Ealing & Hounslow: Dr Geetali Shama (Geetali.sharma@nhs.net)

Brent: Dr Bina Modi (bina.modi@nhs.net);

Harrow: Dr Bina Modi and Dr Bushra Khawaja (bina.modi@nhs.net, bkhawaja@nhs.net)

Hillingdon: Dr Bushra Khawaja (bkhawaja@nhs.net)

NWL FIT Compliance as at July 2025



#### **CANCER SCREENING**

# WSIC DASHBOARD: HOW TO UTILISE THE DASHBOARD TO IDENTIFY UNSCREENED POPULATIONS TO ENABLE TARGETED INTERVENTIONS AND FOCUSED OUTREACH

FOR INFORMATION: ALL PRACTICE STAFF

RM Partners Cancer Alliance, in collaboration with the North West London ICB Business Intelligence Team, has released a new demonstration video for the NWL WSIC Cervical Cancer Screening Dashboard.

Presented by Narinder Sinclair, RM Partners Cervical Screening Lead at NWL ICB, the video showcases how Primary Care Networks (PCNs) and the Integrated Care System (ICS) can utilise the dashboard to analyse cervical screening data at borough, PCN, and practice levels. This tool supports the identification of unscreened populations, enabling targeted interventions and focused outreach.

The demonstration video is available on the <u>WSIC YouTube</u> <u>Channel</u>. You can access the video directly using this <u>link</u>.

### The WSIC Cancer Screening User Guide is available here.

Please note that a WSIC account is not required to access the NWL Cervical Cancer Screening Dashboard. Access is available as long as you are connected to an HSCN secured network.





You can access the NWL WSIC Cervical Cancer Screening Dashboard via <u>ICS Analytics</u> <u>Guest Site</u>.

If you experience any access issues, please reach out to your local IT team.

For questions about the Cervical Cancer Screening Dashboard, please email <a href="mailto:nhs.nwl.wsicsupport@nhs.net">nhs.nwl.wsicsupport@nhs.net</a>.